12-01-2021, 01:18 AM
The head of BioNTech, Ugur Shahin, assessed the effectiveness of the Comirnaty vaccine, developed by the German company BioNTech (Biontek) together with the American partner Pfizer (Pfizer), against the new omicron strain of coronavirus. His words are quoted by Reuters.
Shaheen pointed out that the drug probably provides protection against the severe course of the disease, referring to those cases when patients require hospitalization or intensive care. "We believe that, most likely, people will have significant protection from the severe course of the disease caused by the omicron strain," he explained.
The head of the company added that laboratory tests will be conducted over the next two weeks to find out how much antibodies in the blood of people who have received two or three doses of the Comirnaty vaccine are capable of suppressing a new type of coronavirus.
Shahin noted that the third, booster dose of vaccination will provide a sufficient level of protection compared to those who received only two doses. According to him, there is no cause for concern, but anxiety is caused only by those patients who are not vaccinated at all.
Earlier, the head of Rospotrebnadzor, Anna Popova, said that all existing COVID-19 vaccines in Russia are effective against the omicron strain of coronavirus. She added that PCR testing, which is carried out in Russia, is also able to identify a new strain. According to the latest estimates, the omicron strain of coronavirus has not been detected in Russia.
On November 11, a new strain of coronavirus was detected in South Africa under the code B.1.1.529. The first cases of infection were registered on November 24.
Our partners today:
http://lifeyogaworld.com/?URL=drdoping.com
http://www.anorexicnudes.net/cgi-bin/atc...oping.com/
http://www.aitaina.jp/m/mt4i/index.cgi?i...oping.com/
http://www.basejumper.com/cgi-bin/forum/...oping.com/
http://www.aspheute.com/service/3w_link....oping.com/
Shaheen pointed out that the drug probably provides protection against the severe course of the disease, referring to those cases when patients require hospitalization or intensive care. "We believe that, most likely, people will have significant protection from the severe course of the disease caused by the omicron strain," he explained.
The head of the company added that laboratory tests will be conducted over the next two weeks to find out how much antibodies in the blood of people who have received two or three doses of the Comirnaty vaccine are capable of suppressing a new type of coronavirus.
Shahin noted that the third, booster dose of vaccination will provide a sufficient level of protection compared to those who received only two doses. According to him, there is no cause for concern, but anxiety is caused only by those patients who are not vaccinated at all.
Earlier, the head of Rospotrebnadzor, Anna Popova, said that all existing COVID-19 vaccines in Russia are effective against the omicron strain of coronavirus. She added that PCR testing, which is carried out in Russia, is also able to identify a new strain. According to the latest estimates, the omicron strain of coronavirus has not been detected in Russia.
On November 11, a new strain of coronavirus was detected in South Africa under the code B.1.1.529. The first cases of infection were registered on November 24.
Our partners today:
http://lifeyogaworld.com/?URL=drdoping.com
http://www.anorexicnudes.net/cgi-bin/atc...oping.com/
http://www.aitaina.jp/m/mt4i/index.cgi?i...oping.com/
http://www.basejumper.com/cgi-bin/forum/...oping.com/
http://www.aspheute.com/service/3w_link....oping.com/
![[图: 96af0c11de75303367c5d.jpg]](https://telegra.ph/file/96af0c11de75303367c5d.jpg)